Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Poolbeg Pharma Ltd. ( (GB:POLB) ) has provided an update.
Poolbeg Pharma plc has announced a proposed fundraising to raise approximately £4.1 million through the issuance of new ordinary shares. This fundraising will support the company’s ongoing clinical trials, including the Phase 2a trial for POLB 001, a potential breakthrough treatment for cancer immunotherapy-induced Cytokine Release Syndrome, and an oral GLP-1 proof of concept trial aimed at the obesity market. The successful execution of these trials could unlock significant market opportunities and potential partnerships, enhancing the company’s industry positioning and stakeholder value.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs. The company’s clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity, with the development of an oral encapsulated glucagon-like peptide receptor (GLP-1R) agonist.
Average Trading Volume: 1,108,755
Technical Sentiment Signal: Sell
See more insights into POLB stock on TipRanks’ Stock Analysis page.